Brokerages Set Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Price Target at $245.94

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have received a consensus rating of “Moderate Buy” from the nineteen analysts that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $252.8824.

JAZZ has been the topic of several recent analyst reports. Sanford C. Bernstein reiterated a “market perform” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, June 9th. Bank of America boosted their price objective on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Weiss Ratings raised shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, June 29th. TD Cowen lifted their price target on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Barclays lifted their price target on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total value of $1,442,820.00. Following the completion of the sale, the director directly owned 366,682 shares of the company’s stock, valued at $88,176,020.54. This represents a 1.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Heather Ann Mcsharry sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total value of $482,000.00. Following the transaction, the director owned 18,449 shares in the company, valued at $4,446,209. This represents a 9.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 13,098 shares of company stock valued at $3,131,906. Corporate insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Arista Wealth Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the second quarter worth approximately $241,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter worth $61,000. GAMMA Investing LLC boosted its stake in Jazz Pharmaceuticals by 18.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $339,000 after purchasing an additional 223 shares during the period. Harbor Investment Advisory LLC grew its position in Jazz Pharmaceuticals by 349.2% during the 2nd quarter. Harbor Investment Advisory LLC now owns 292 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 227 shares during the last quarter. Finally, Versant Capital Management Inc increased its stake in Jazz Pharmaceuticals by 14.9% in the second quarter. Versant Capital Management Inc now owns 2,357 shares of the specialty pharmaceutical company’s stock valued at $568,000 after purchasing an additional 305 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 2.8%

Shares of NASDAQ JAZZ opened at $236.97 on Tuesday. The business has a 50-day moving average of $233.64 and a two-hundred day moving average of $198.68. The company has a market capitalization of $14.89 billion, a price-to-earnings ratio of -11,842.58, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. Jazz Pharmaceuticals has a 1 year low of $105.00 and a 1 year high of $250.49. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The business had revenue of $1.07 billion for the quarter. On average, analysts forecast that Jazz Pharmaceuticals will post 21.9 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.